Navigation Links
Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Date:8/13/2008

SAN MATEO, Calif., Aug. 13 /PRNewswire/ -- Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the completion of a $19 Million equity financing. New investors Caxton Advantage Life Sciences Fund (New York, NY) and HBM BioCapital (Cayman Islands) led the financing, and Rachel Leheny, Ph.D. Managing Director of Caxton Advantage Venture Partners (the General Partner of Caxton Advantage Life Sciences Fund) will join Anthera's Board of Directors. The financing also included existing investors VantagePoint Venture Partners, Sofinnova Ventures, Pappas Ventures and Mitsubishi International Corporation.

In addition, the company announced the appointment of Christopher S. Henney as Chairman of the Board. Dr. Henney has served as an independent director of Anthera since 2006. Dr. Henney is a co-founder of three major publicly held U.S. biotechnology companies: Immunex‚ ICOS and Dendreon‚ and has been associated with the formation of several others. Most recently Dr. Henney has served as Chairman and Chief Executive Officer of Dendreon (Nasdaq: DNDN) and as Chairman of SGX Pharmaceuticals (Nasdaq: SGXP) and of Oncothyreon (Nasdaq: ONTY).

"We are delighted to have Caxton Advantage and HBM, two premier health care funds, lead
'/>"/>

SOURCE Anthera Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 According to ... Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web ... Forecasts & Trends to 2018", published by MarketsandMarkets, analyzes ... geographies such as North America , ... , and the Rest of the World (RoW). ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today a ... to provide access to Nanosyn,s microfluidics screening and ... for novel small molecule therapeutics. ... work with FORMA Therapeutics to explore key pathways ... FORMA Therapeutics, decision to work with us is ...
(Date:7/29/2014)... Colo. , July 29, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... Times for taking a strong position in opposition ... Sunday, July 27, 2014 publication.  The New York ... and articles this week exploring the issue called ...
(Date:7/29/2014)... Denver, CO (PRWEB) July 29, 2014 ... and soiled linen collection and transport solutions for hospitals, ... Society for Healthcare Engineering (ASHE) Annual Conference & Technical ... TransVac will present its technology for making hospitals cleaner, ... operational costs over the hospital’s life cycle. Staff ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... LOUIS, Jan. 24 The National Academy of,Sciences ... Fraley, Ph.D.,chief technology officer and executive vice president ... the Industrial Application of Science. This,prize is awarded ... importance and with significant, beneficial applications in,industry -- ...
... Bard, professor of chemistry and biochemistry at The University ... Prize in Chemistry jointly with Professor William Moerner of ... of education, Professor Yuli Tamir, was given to the ... of science, single-molecule spectroscopy and imaging. , The $100,000 ...
... million grows 32% year-over-year, - Operating income increases 47.7%, diluted ... - Backlog increases 41% to a record of ... - Net quarterly book-to-burn ratio equates to 1.9, BOSTON, ... its financial results for the,second quarter ended December 31, 2007., ...
Cached Biology Technology:National Academy of Sciences Recognizes Monsanto's Chief Technology Officer for Development of Agricultural Biotechnology 2PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 9PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 10
(Date:7/29/2014)... sometimes need to get back to basics. UC ... study the impacts of the bumphead parrotfish ( ... two remote locations in the central Pacific Ocean. ... simulation, McCauley, an assistant professor in the Department ... colleagues sought to understand whether the world,s largest ...
(Date:7/29/2014)... effects of a stroke is an immensely complex ... well as effective therapy. Advancing such knowledge to ... primary focus of research by Sergei Adamovich, associate ... NJIT faculty more than a decade ago. It ... funding from sources such as the National Institutes ...
(Date:7/29/2014)... (UM SOD) and Medicine (UM SOM) jointly announced ... million grant award from the National Institute of ... Institutes of Health to study the causes, prevention ... which renews a previous $12 million five-year NIAID-funded ... research by studying chlamydial and gonorrheal diseases as ...
Breaking Biology News(10 mins):Underwater elephants 2Underwater elephants 3Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4
... islet cells from pigs may be used in clinical ... diabetes. This key finding was the discovery ... Institute for Immunology & Transplantation at the University of ... in the prestigious scientific journal Nature Medicine in March ...
... MICROSCOPY -- A chorus of signals . . . ... scanning probe microscopy, moves the field towards probing energy ... probe microscopes measure the cantilevers movements over the surface ... excitation excites and detects response over a continuous band ...
... of UPMC have identified a potential target for ... the most prevalent sexually transmitted bacterial infection in ... Darville, MD, chief of the Division of Pediatric ... of Chlamydia that, when investigated in an animal ...
Cached Biology News:Breakthrough research identifies how cells from pigs may cure diabetes 2Story tips from the US Department of Energy's Oak Ridge National Laboratory, September 2007 2Story tips from the US Department of Energy's Oak Ridge National Laboratory, September 2007 3Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: